SK Biopharmaceuticals Co., Ltd. (KRX:326030)

South Korea flag South Korea · Delayed Price · Currency is KRW
88,400
-700 (-0.79%)
At close: Jun 2, 2026
Market Cap6.92T -10.7%
Revenue (ttm)790.25B +36.7%
Net Income348.81B +38.9%
EPS4,452.58 +38.8%
Shares Out 78.31M
PE Ratio19.85
Forward PE21.62
Dividendn/a
Ex-Dividend Daten/a
Volume282,903
Open87,700
Previous Close89,100
Day's Range87,300 - 89,900
52-Week Range87,300 - 144,100
Beta0.79
AnalystsBuy
Price Target137,923.08 (+56.02%)
Earnings DateMay 7, 2026

About SK Biopharmaceuticals

SK Biopharmaceuticals Co., Ltd., a pharmaceutical company, engages in the research, development, and commercialization of drugs for the treatment of central nervous system disorders. The company offers Cenobamate, an anti-seizure medication for the treatment of epilepsy and Solriamfetol medication. It develops Carisbamate that is in Phase 3 trials to treat lennox-gastaut syndrome; Relenopride, which is in Phase 2 clinical trials for treatment of rare neurological disease; SKL24741, which is in Phase 1 clinical trials for the treatment of epilep... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1993
Employees 246
Stock Exchange Korea Stock Exchange
Ticker Symbol 326030
Full Company Profile

Financial Performance

In 2025, SK Biopharmaceuticals's revenue was 706.74 billion, an increase of 29.06% compared to the previous year's 547.60 billion. Earnings were 266.95 billion, an increase of 10.89%.

Financial Statements